Veterinary Neurodegenerative Disease Diagnostics Market Summary
The market for veterinary neurodegenerative disease diagnostics was valued at USD 365.8 million in 2024 and is expected to increase at a compound annual growth rate (CAGR) of 8.69% from 2025 to 2030, reaching USD 596.1 million. The growing prevalence of neurological illnesses in companion animals, expanding pet ownership and spending, and technical developments in veterinary neurology are some of the major drivers propelling the market.
Key Market Trends & Insights
- North America dominated the veterinary neurodegenerative disease diagnostics market with the largest revenue share of 38.25% in 2024.
- The veterinary neurodegenerative disease diagnostics market in the U.S. is anticipated to grow at a significant CAGR over the forecast period.
- Based on indication, the cognitive dysfunction segment led the market with the largest revenue share of 40.35% in 2024.
- The companion segment had the biggest market revenue share in 2024, according to animal type.
- The imaging segment had the biggest market revenue share in 2024, according to diagnostic tests.
Market Size & Forecast
- 2024 Market SizeUSD 365.8 Million
- 2030 Projected Market SizeUSD 596.1 Million
- CAGR (2025-2030)8.69%
- North AmericaLargest market in 2024
- Asia PacificFastest growing market
Additionally, expanding pet ownership, growing awareness of animal health, and rising investments in veterinary infrastructure are all contributing to the veterinary neurodegenerative medicine industry's growth in emerging markets. The construction of veterinary clinics, mobile care units, and diagnostic labs with cutting-edge neurological equipment like MRI and CT is booming across Asia-Pacific, Latin America, and some parts of Africa.
Furthermore, a Mad Barn post from April 2025 claims that Arabian horses have a hereditary predisposition to a number of autosomal recessive disorders. One of these is Cerebellar Abiotrophy (CA), a neurodegenerative condition where the loss of neurons in the cerebellum impairs balance and motor coordination. The disease develops when an afflicted foal inherits two faulty copies of a gene from its carrier parents. Their breeding history greatly influences the frequency of these illnesses in Arabian horses. In the past, Arabian horses were shipped in small quantities from the Middle East to other countries to start new breeding populations. Genetic bottlenecks caused by these small founder populations resulted in a decrease in genetic diversity. Heritable neurological disorders like CA became more common as a result of the gene pool's decreased genetic diversity, which raised the chance of mating between carriers of the same recessive mutation.
This hereditary vulnerability is one of the main factors propelling the expansion of the veterinary neurodegenerative medicine sector. The need for specialist veterinary treatments, such as sophisticated genetic testing, neurological diagnostics, and long-term disease care, is enhanced by Arabian horses' higher risk of inherited problems. To find carriers and stop the spread of these illnesses through selective breeding, breeders and owners increasingly depend more on DNA screening. To manage afflicted animals, veterinarians also need neuroimaging technologies, disease-specific medicines, and supportive treatments. Due to the Arabian horse's high emotional and financial worth, owners are more inclined to spend money on state-of-the-art medical treatments, which encourages more innovation and expenditure in the veterinary industry's equine neurology sector.
Additionally, the adoption of pet insurance plays a major role in the market expansion since it lessens the financial strain on pet owners and increases access to cutting-edge diagnostics and treatments. Animal neurological issues like intervertebral disc degeneration, degenerative myelopathy, and cerebellar abiotrophy often require costly treatments such as MRI/CT scans, long-term medication, specialist visits, and sometimes surgery. The hefty expense can discourage pet owners from seeking thorough care if they do not have insurance. However, more owners can now afford these treatments thanks to the growing popularity of pet insurance, which raises demand for long-term therapies, specialist neurology services, and neurodiagnostic instruments.
Market Concentration & Characteristics
There is significant market concentration in the veterinary neurodegenerative disease diagnostics sector, and the market is expanding at an accelerated rate. Rapid technical improvements are a primary factor contributing to the market's expansion. For example, a National Library of Medicine article claims that advanced diagnostic imaging technologies, which were previously only available at specialized veterinary clinics or research institutions, have significantly advanced in veterinary medicine recently. These days, nuclear medicine (such as PET and SPECT scans), computed tomography (CT), magnetic resonance imaging (MRI), and hybrid imaging modalities are becoming more and more prevalent in veterinary clinics. These technologies enable more precise diagnosis and improved comprehension of complicated disorders, especially musculoskeletal and neurodegenerative diseases, by providing detailed, high-resolution images of the internal components of animals.
Innovation is prevalent and is fueled by developments in digital health integration, medicinal development, and diagnostic technology. Advanced imaging technologies, such as hybrid PET/MRI systems and high-field MRI, are improving the early and accurate identification of neurological diseases in animals. At the same time, advances in genetic testing and molecular diagnostics make it possible to more precisely identify hereditary neurodegenerative illnesses.
Due to the growing need for sophisticated diagnostic solutions and the strategic initiatives of major competitors to bolster their technological know-how and expand their worldwide reach, the market sees a moderate amount of mergers and acquisitions. The German diagnostics company Synlab, for example, which operates in the human and animal health sectors, decided to sell its animal health diagnostics segment to Mars Inc. in August 2023. Under Mars' ownership, we expect SYNLAB VET to grow and develop further, allowing Synlab to focus on its primary business.
Regulations greatly influence the veterinary neurodegenerative disease diagnostics sector, shaping market access, approval procedures, and product development. Strict regulations are enforced by regulatory organizations like the European Medicines Agency (EMA), the U.S. Department of Agriculture (USDA), and national veterinary authorities to guarantee the dependability, safety, and accuracy of diagnostic tests. These rules require extensive quality control and validation processes, which might lengthen the time and expense of introducing novel diagnoses to the market. However, by ensuring that diagnostic instruments meet strict requirements, these regulations also enhance the trust of consumers and veterinarians.
Since alternative diagnostic techniques are available but frequently vary in quality, speed, and applicability, the degree of product substitutions in the veterinary neurodegenerative disease diagnostics sector is modest. For instance, although they are not as accurate as more sophisticated imaging methods like MRI or CT scans, conventional clinical neurological tests and behavioral assessments can occasionally be used as early diagnostic alternatives.
To capitalize on the growing need for cutting-edge diagnostic solutions, businesses in the veterinary neurodegenerative disease diagnostics sector are putting more of an emphasis on regional expansion. Due to reasons such as the rise in pet ownership, rising veterinary healthcare costs, and the continuous development of veterinary infrastructure in these regions, major players are concentrating on developing markets in Asia-Pacific and Latin America.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Product Insight
In 2024, the sector with the biggest market revenue share was consumables, reagents, and kits. Advanced molecular and biochemical testing, which is essential for identifying complicated neurodegenerative disorders that are otherwise challenging to identify by clinical signs alone, is made possible by these tools for veterinarians. For instance, PCR-based genetic testing kits aid in the identification of particular gene abnormalities that cause hereditary disorders such as degenerative myelopathy in dogs or cerebellar atrophy in Arabian horses. Similarly, neuro-specific biomarkers that show inflammation or injury to neurons, including glial fibrillary acidic protein or neurofilament light chain, can be measured by ELISA kits. These specialist kits' accessibility enables early diagnosis, which promotes improved disease treatment and enhances the health of animals.
The inherent benefits of consumables and reagents are another factor contributing to their dominance in this sector. They provide consistency and dependability in test results because they are usually single-use, standardized, and simple to incorporate into current veterinary lab procedures. This repeatability creates a steady and recurrent demand, which supports the market's ongoing expansion. Additionally, by offering quick, accurate, and affordable alternatives, diagnostic kits lessen the need for costly and time-consuming procedures. Businesses have taken advantage of this by creating specialized neurodegenerative diagnostic tools that enhance clinical judgment, such as IDEXX Laboratories and Zoetis. These consumables and kits are indispensable tools because of their speed, precision, and convenience, which promotes their broad use in veterinary clinics and specialist centers around the world.
Animal Type Insights
The companion segment accounted for the largest market revenue share in 2024. The segment is also anticipated to grow at the fastest CAGR over the forecast period. This growth can be attributed to factors such as the increasing adoption of pet insurance, rising pet ownership, and high prevalence of neurodegenerative diseases in companion animals. According to a March 2025 article published by PetFoodIndustry, pet ownership continues to rise in the United States, with 94 million households currently owning at least one pet, an increase from 82 million households in 2023. Dog ownership has reached 51% of households, representing approximately 68 million dogs, while cats are present in 37% of households, totaling around 49 million cats.
Additionally, more pets are being diagnosed with issues like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction syndrome because people are more aware of these conditions and there are better ways to diagnose them. For example, degenerative myelopathy, a progressive spinal cord disorder primarily affecting older dogs, is becoming more commonly recognized, leading to greater demand for advanced diagnostic tests like genetic screening and MRI imaging to confirm the diagnosis. Similarly, cognitive dysfunction syndrome affects aging dogs and cats, prompting pet owners and veterinarians to seek specialized treatments and monitoring tools to manage the condition.
Diagnostic Tests Insight
The imaging segment accounted for the largest market revenue share in 2024 due to its critical role in the early and accurate diagnosis of neurological disorders in animals, such as epilepsy, brain tumors, and degenerative myelopathy. Advanced imaging techniques like MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans are essential for visualizing structural and functional changes in the animal brain and spinal cord, enabling veterinarians to identify and monitor disease progression. For example, MRI is commonly used in dogs to detect brain lesions associated with canine cognitive dysfunction, a condition similar to Alzheimer’s in humans. The increasing availability of specialized veterinary imaging centers and the growing demand for precise, non-invasive diagnostic tools further contribute to the segment’s dominance in the market.
The biomarker diagnostic tests segment is anticipated to grow at the fastest CAGR over the forecast period. The tests allow early detection, monitoring, and personalized treatment of neurological diseases in animals. These tests identify specific biological indicators-such as proteins, enzymes, or genetic markers-linked to conditions like canine cognitive dysfunction or feline spongiform encephalopathy. For example, elevated levels of certain cerebrospinal fluid (CSF) proteins, such as tau or amyloid-beta, can indicate neurodegeneration in dogs, mirroring Alzheimer’s biomarkers in humans. As more pet owners want specific and preventive care for their animals, biomarker diagnostics give veterinarians important tools to act quickly, greatly improving how well they can manage neurodegenerative diseases.
Indication Insights
The cognitive dysfunction segment led the market with the largest revenue share of 40.35% in 2024, due to its high prevalence across both companion animals and the need for rapid, accurate detection to prevent outbreaks. Canine Cognitive Dysfunction Syndrome (CDS) in dogs and cats is frequently overlooked and underdiagnosed, despite being a common age-related neurodegenerative disorder, according to an article published by Today's Veterinary Practice in December 2024. Research based on pet owner surveys indicates that the prevalence of CDS in dogs varies widely, ranging from approximately 22.5% to as high as 73.5%. For example, a survey targeting owners of dogs aged seven years and older found that about 75% of these dogs exhibited at least one behavioral change consistent with CDS, such as disorientation, altered interactions, sleep disturbances, or changes in activity levels.
Additionally, the same article mentions that a 2024 study found a 15% diagnosis rate using CDS screening questionnaires, showing that veterinarians are increasingly recognizing and diagnosing Canine Cognitive Dysfunction Syndrome (CDS). Although this rate appears lower than some owner-reported prevalence estimates, it highlights the emerging use of formal, standardized screening tools to identify neurodegenerative conditions that were previously underdiagnosed or overlooked. This increased focus on systematic screening reflects a shift toward early detection and intervention, which is crucial for managing CDS effectively.
End Use Insight
The veterinary hospitals and clinics segment accounted for the largest market revenue share in 2024, as they serve as the primary points of care where animals are first assessed and diagnosed. Unlike diagnostic laboratories that primarily focus on specialized testing, veterinary hospitals and clinics offer comprehensive, on-site diagnostic services combined with clinical evaluation, allowing for quicker decision-making and immediate treatment planning. This convenience and integrated care model encourages pet owners to seek timely veterinary attention, thereby increasing demand for neurodegenerative disease diagnostics. In addition, veterinary hospitals and clinics often invest in advanced imaging technologies such as MRI and CT scanners, enabling in-house neurodiagnostic capabilities that reduce turnaround time compared to sending samples to external labs.
The veterinary diagnostic laboratories segment is expected to grow at the fastest CAGR over the forecast period. These laboratories offer access to advanced diagnostic tools such as genetic testing, biomarker assays, and imaging analysis, which many veterinary clinics may not have the resources or equipment to perform in-house. By acting as central locations for advanced testing, they help identify and track brain diseases in dogs, such as cognitive dysfunction, degenerative myelopathy, and cerebellar abiotrophy.
Regional Insights
North America dominated the veterinary neurodegenerative disease diagnostics market with the largest revenue share of 38.25% in 2024. This leadership position is attributed to the region’s advanced veterinary healthcare infrastructure, extensive adoption of cutting-edge technologies, high disposable income levels, and the presence of key industry players. We anticipate these companies' continued strategic initiatives to further accelerate growth within the region. For example, global pet healthcare innovators such as Zoetis and IDEXX Laboratories, Inc., provide advanced diagnostic services, including MRI and CT scans, reinforcing their market presence.
U.S. Veterinary Neurodegenerative Disease Diagnostics Market Trends
The veterinary neurodegenerative disease diagnostics market in the U.S. is anticipated to grow at a significant CAGR over the forecast period. The country’s large pet population and increasing pet expenditure are key drivers of market growth. For example, according to the American Pet Products Association (APPA), veterinary care and routine veterinary visits generated expenditures of USD 41.4 billion in 2024. This substantial spending underscores the increasing prioritization of pet health and wellness among pet owners, which directly supports the market growth. As more owners invest in regular veterinary care, there is greater demand for advanced diagnostic services, including those for neurodegenerative conditions. Routine visits provide critical opportunities for the early detection and monitoring of neurological disorders, driving the need for sophisticated diagnostic tools and technologies, thereby fueling market expansion.
Europe Veterinary Neurodegenerative Disease Diagnostics Market Trends
The veterinary neurodegenerative disease diagnostics market in Europe is poised for robust growth, fueled by factors such as the increasing prevalence of neurological diseases, rising pet ownership rates, and expanding uptake of pet insurance. The 2024 FEDIAF report highlights that approximately 50% of European households own pets, accounting for 166 million out of 352 million across Europe, indicating a growing customer base for veterinary services. As pets are increasingly viewed as family members, there is heightened demand for comprehensive veterinary care, including routine screenings and early disease detection. This shift drives market expansion by encouraging veterinary clinics and diagnostic laboratories to adopt and offer advanced, precise, and rapid diagnostic technologies, thereby meeting the evolving needs of pet owners and improving disease management outcomes.
The presence of leading insurance providers offering comprehensive coverage for veterinary diagnostic services significantly contributes to market growth within the country. Major players such as PetPlan, Trupanion, Nationwide, and Healthy Paws provide extensive insurance policies that encompass a broad spectrum of veterinary needs, including diagnostic testing, in-person and telehealth consultations, surgical procedures, and various treatments. By reducing the financial burden associated with advanced diagnostic services, these insurance solutions lower barriers to care, enabling pet owners to pursue timely and regular veterinary visits. This lower cost and easier access encourage more veterinary clinics to use advanced diagnostic technologies and tools, as pet owners with insurance are more likely to pay for detailed tests and catch diseases early, which helps the market grow faster.
Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Trends
The veterinary neurodegenerative disease diagnostics market in Asia Pacific plays a pivotal role in driving market growth, supported by several critical factors. Rapid urbanization and rising disposable incomes have led to increased pet ownership across countries such as China, India, Japan, and Australia. For example, China has seen a substantial surge in pet adoption, with millions of new dog and cat owners emerging annually, which directly increases demand for veterinary healthcare services, including advanced diagnostics. In addition, growing awareness about pet health and wellness is encouraging owners to seek early diagnosis and treatment for neurodegenerative diseases, fueling market expansion.
The India veterinary neurodegenerative disease diagnostics market is growing at a rapid pace, driven by rising pet ownership, expanding veterinary infrastructure, and increasing demand for advanced diagnostic technologies. As of 2024, the country will have over 35 million pet dogs and approximately 2.5 million pet cats, reflecting a growing emphasis on companion animal health. This increase in pet ownership is also changing how people view pets, as they are now seen more as important family members, which is raising the need for thorough veterinary care, including early detection and treatment of brain diseases like canine cognitive dysfunction and degenerative myelopathy.
Latin America Veterinary Neurodegenerative Disease Diagnostics Market Trends
The veterinary neurodegenerative disease diagnostics market in Latin America is emerging as a promising growth region, driven by rising pet ownership, increasing awareness of animal health, and expanding access to veterinary care. Countries such as Brazil and Argentina are witnessing a growing middle-class population with higher disposable incomes, which has led to a surge in pet adoption and a shift toward treating pets as family members. For instance, Brazil is among the top countries globally in terms of pet population, with over 149 million pets as of 2024, including a significant number of dogs and cats, prime candidates for neurodegenerative disease diagnostics.
The Brazil veterinary neurodegenerative disease diagnostics market is witnessing significant advancements in infrastructure and technology. The adoption of sophisticated diagnostic tools, such as molecular diagnostics and advanced imaging technologies, is enhancing the capacity for early and accurate diagnosis of neurodegenerative diseases in pets. These technological advancements are making advanced diagnostics more accessible across the country, further fueling market growth. Moreover, around 91% of Brazilian pet owners prioritize their pets' health, reflecting a growing demand for comprehensive veterinary care, including diagnostics for neurodegenerative diseases.
Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Trends
The veterinary neurodegenerative disease diagnostics market in the Middle East & Africa (MEA) region, comprising countries such as South Africa, Saudi Arabia, the UAE, and Kuwait, is expected to witness steady growth, driven by rising pet ownership, improving veterinary infrastructure, and growing investment in animal healthcare. In Gulf countries such as the United Arab Emirates and Saudi Arabia, pet humanization is on the rise due to lifestyle changes and increasing disposable incomes. This trend has led to greater demand for high-quality veterinary services, including advanced diagnostics for age-related and neurological conditions in companion animals like dogs and cats.
The South Africa veterinary neurodegenerative disease diagnostics market is playing an increasingly pivotal role in the market growth, driven by rising pet ownership, expanding veterinary infrastructure, and the adoption of advanced diagnostic technologies. Approximately 45% of South African adults are pet owners, with dogs being the most popular choice, accounting for 78% of pet-owning households. This growing pet population, along with the trend of treating pets as integral family members, increases the demand for comprehensive veterinary care, including diagnostics for neurodegenerative conditions such as canine cognitive dysfunction and degenerative myelopathy.
Key Veterinary Neurodegenerative Disease Diagnostics Company Insights
The veterinary neurodegenerative disease diagnostics industry exhibits moderate competitiveness, marked by the presence of both established industry leaders and emerging entrants. The competitive landscape is primarily shaped by rapid technological progress and a consistent demand for innovative diagnostic solutions. To reinforce their market presence and expand their product portfolios, leading companies are increasingly engaging in strategic initiatives such as mergers and acquisitions, partnerships, and the launch of advanced diagnostic technologies. These approaches enable them to strengthen their capabilities, address shifting customer needs, and sustain a competitive advantage within an evolving market environment.
Key Veterinary Neurodegenerative Disease Diagnostics Companies
The following are the leading companies in the veterinary neurodegenerative disease diagnostics market. These companies collectively hold the largest market share and dictate industry trends.
- Zoetis
- Virbac
- Life Diagnostics
- ACUVET BIOTECH
- Merck & Co., Inc.
- IDEXX Laboratories, Inc.
- MIRNA Diagnostics Ltd.
- Mercodia AB
- Antech Diagnostics, Inc.
- Avacta Animal Health Limited
Recent Developments
-
In October 2024, WOORIEN Co., Ltd., a veterinary imaging equipment and solutions specialist, introduced the 'MyVet CT Plus,' designed to accommodate various animal sizes-from small lizards to large retrievers. The MyVet CT Plus delivers significantly faster and higher-quality imaging, reducing acquisition time by at least 45% compared to its predecessor, with potential reductions of up to 80%.
-
In March 2024, Animed Veterinary Group started its mobile CT service visits at Animed Veterinary Hospital and Nine Mile Veterinary Group—both members of CVS Group Plc—once every four weeks.
-
In January 2024, IDEXX Laboratories launched the IDEXX inVue Dx Cellular Analyzer, a new technology that changes how cytologic analysis is done in veterinary clinics by eliminating the need for slides and offering quick, reliable results with detailed insights using AI imaging.
-
In August 2020, IDEXX Laboratories launched a new ImageVue DR30 Digital Imaging System to enhance its digital imaging portfolio.
Veterinary Neurodegenerative Disease Diagnostics Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 392.9 million |
|
Revenue forecast in 2030 |
USD 596.1 million |
|
Growth rate |
CAGR of 8.69% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018-2023 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Animal type, product, diagnostic tests, indication, end use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Zoetis; Virbac; Life Diagnostics; ACUVET BIOTECH; Merck & Co., Inc.; IDEXX Laboratories, Inc.; MIRNA Diagnostics Ltd; Mercodia AB; Antech Diagnostics, Inc; Avacta Animal Health Limited |
|
Customization scope |
The purchase includes free report customization, equivalent to up to 8 analysts' working days. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Global Veterinary Neurodegenerative Disease Diagnostics Market Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, MIR has segmented the global veterinary neurodegenerative disease diagnostics market report based on animal type, product, diagnostic tests, indication, end use, and region.
-
Product Outlook (Revenue, USD Million, 2018-2030)
-
Consumables, Reagents & Kits
-
Equipment & Instruments
-
-
Diagnostic Tests Outlook (Revenue, USD Million, 2018-2030)
-
Imaging
-
MRI (Magnetic Resonance Imaging)
-
CT (Computed Tomography)
-
Others
-
-
Biomarker Diagnostic Tests
-
CSF (Cerebrospinal Fluid) biomarkers
-
Blood-based biomarkers
-
Others
-
-
Others
-
-
Animal Type Outlook (Revenue, USD Million, 2018-2030)
-
Livestock
-
Sheep
-
Cattle
-
Others
-
-
Companion
-
Canine
-
Feline
-
Equine
-
Others
-
-
-
Indication Outlook (Revenue, USD Million, 2018-2030)
-
Cognitive Dysfunction
-
Cerebellar Abiotrophy
-
Spongiform Encephalopathies
-
Others
-
-
End Use Outlook (Revenue, USD Million, 2018-2030)
-
Veterinary Hospitals and Clinics
-
Veterinary Diagnostic Laboratories
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2018-2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
India
-
China
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy